D-0297-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0297-2021 was initiated by Teva Pharmaceuticals USA on Feb 15, 2021 and is designated Class II. Reason for recall: Chemical contamination; Unknown brown residue adhering to the inside of one vial. The recall status is terminated (terminated Aug 26, 2021). Affected quantity: 9,452 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 10, 2021
Initiation Date
Feb 15, 2021
Termination Date
Aug 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9,452 cartons

Product description

Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 25x2mL Single Dose Vials, Rx only, Distributed by Teva Pharmaceuticals, USA, Inc., Parsippany, NJ Vial NDC 0703-4502-01 (vial) NDC# 0703-4502-04 (tray)

Reason for recall

Chemical contamination; Unknown brown residue adhering to the inside of one vial.

Distribution pattern

Nationwide, including Puerto Rico

Code information

Lot # 31325335B, exp. date 07/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0297-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0297-2021. Report a data issue: hello@regdatalab.com.